New Mantle Cell Treatment on US FDA Fast Track

Submitted by mike Wed 11/03/2004

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

The US Food and Drug Administration (FDA) has granted the drug VELCADE (bortezomib) fast track designation for relapsed and refractory mantle cell lymphoma (MCL). MCL is an aggressive form of non-Hodgkin's lymphoma (NHL) which accounts for approximately six percent of all lymphomas. Currently, VELCADE is being evaluated as a single agent in a multicenter Phase II clinical trial for the treatment of mantle cell lymphoma. It is expected that interim data from the trial will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in 2005.

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.